This document is an internal Drug Enforcement Administration quality system document. The effective period of the document is March 23, 2018 to October 7, 2019 and it is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents...

This document is an internal Drug Enforcement Administration quality system document. The effective period of the document is March 23, 2018 to October 7, 2019 and it is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents...

This document is an internal Drug Enforcement Administration quality system document. The effective period of this document is April 24, 2018 to September 9, 2019 and it is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents...

Robert W. Patterson: Before the Subcommittee on Oversight and Investigations Committee on Energy and Commerce U.S. House of Representatives

Susan A. Gibson: Before the Subcommittee on Health Energy and Commerce Committee United States House of Representatives, for a Hearing Entitled “Combating the Opioid Crisis: Helping Communities Balance Enforcement and Patient Safety”

The Drug Enforcement Administration (DEA) Philadelphia Field Division (PFD) conducted an assessment of laboratory-analyzed drug seizures. Some seized cocaine exhibits were found to contain cocaine and fentanyl, as well as a combined cocaine and fentanyl presence in overdose death toxicology reporting. This analysis was conducted in response to reported increases...

The Drug Enforcement Administration (DEA) Philadelphia Field Division (PFD) conducted a review of laboratory-analyzed drug seizures for the Commonwealth of Pennsylvania. The resulting analysis of this data formed the basis for estimating the level of drug presence in Pennsylvania and highlighted trends in drug availability between 1999 and 2016.

The Drug Enforcement Administration (DEA) Philadelphia Field Division (PFD) Intelligence Program maintains situational awareness of drug availability, abuse, trafficking patterns, adulterants, concealment methods, etc., through analysis of law enforcement and public health information and data, as well as law enforcement source information.

A review of cocaine exhibits acquired by law enforcement authorities during operations across Florida and analyzed by forensic laboratories during the period from 2016 to 2017 revealed the widespread adulteration of cocaine with fentanyl and fentanyl-related substances. Fentanyl, a Schedule II opioid analgesic approximately 50 times more potent than heroin...

Attorney General Sessions Delivers Remarks at the DEA Graduation Ceremony